Ana gezinime atla Aramaya atla Ana içeriğe atla

Türkiye Romatoloji Derneği ANCA ilişkili (asosiye) vaskülitler hastalık yönetimi kılavuzu

  • Ömer Karadağ
  • , Emine Sarıyıldız
  • , Pınar Akyüz Dağlı
  • , Önay Gerçik
  • , Rıza Can Kardaş
  • , Duygu Şahin
  • , Gizem Sevik
  • , Elif Durak Ediboğlu
  • , Gözde Sevgi Kart Bayram
  • , Tahir Saygın Öğüt
  • , Mehmet Nedim Taş
  • , Gökçe Kenar Artın
  • , Hamit Küçük
  • , Merve Pamukçuoğlu
  • , Serdar Özer
  • , Mehmet Engin Tezcan
  • , Fatma Alibaz
  • , Ahmet Omma
  • , Ebru Damadoğlu
  • , Ebru Aşıcıoğlu
  • Ayten Yazıcı, Deniz Köksal, Kenan Aksu, Haner Direskeneli
  • Hacettepe University
  • Ankara Bilkent Şehir Hastanesi
  • Izmir Democracy University
  • Gazi University
  • University of Health Sciences
  • Marmara University
  • Izmir Katip Celebi University
  • Akdeniz University
  • Manisa Şehir Hastanesi
  • Dokuz Eylul University
  • Kocaeli University
  • Ege University

Araştırma sonucu: Dergiye katkıİnceleme makalesibilirkişi

Özet

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) manifest with involvement of the ear, nose, throat, skin, neurological system, and constitutional symptoms, as well as potentially life-threatening cardiac, renal, and pulmonary organ involvement leading to organ dysfunction. Early diagnosis is critical, necessitating increased awareness among clinicians. Advances in technology have facilitated the use of various laboratory, imaging, and interventional methods for diagnosis, differential diagnosis, and disease monitoring, with composite disease activity indices employed to assess disease activity and organ damage. In patients presenting with systemic features suggestive of AAV, such as cutaneous vasculitis, chronic upper and lower respiratory tract diseases, rapidly progressive renal impairment, or peripheral neuropathy, high-quality antigen-specific assays for proteinase-3 ANCA and myeloperoxidase ANCA should be performed as primary diagnostic tests. Management by multidisciplinary teams experienced in vasculitis is recommended. AAV treatment is divided into remission induction and maintenance phases; induction therapy for organ- or life-threatening disease typically includes glucocorticoids combined with rituximab- or cyclophosphamide-based regimens. Maintenance therapy, often with rituximab, follows remission to prevent relapse. While glucocorticoids remain a cornerstone of induction therapy, studies demonstrate that reduced-dose steroid regimens offer comparable efficacy to standard doses with lower infection risk. The introduction of biologics such as rituximab and mepolizumab has significantly decreased treatment-related damage associated with glucocorticoids and other immunosuppressants. Throughout follow-up, patients should be regularly monitored for treatment-related adverse effects and comorbidities (including hypertension, osteoporosis, and cardiovascular disease) with appropriate lifestyle modifications recommended to optimize long-term outcomes.

Tercüme edilen katkı başlığıTurkish Society for Rheumatology guideline for the management of ANCA-associated vasculitides
Orijinal dilTürkçe
Sayfa (başlangıç-bitiş)131-144
Sayfa sayısı14
DergiJournal of Turkish Society For Rheumatology
Hacim17
Basın numarası3
DOI'lar
Yayın durumuYayınlandı - Kas 2025

BM SKH

Bu sonuç, aşağıdaki Sürdürülebilir Kalkınma Hedefine/Hedeflerine katkıda bulunur

  1. SKH 3 - Sağlık ve Kaliteli Yaşam
    SKH 3 Sağlık ve Kaliteli Yaşam

Keywords

  • Vasculitis
  • comorbidity
  • cyclophosphamide
  • eosinophilic granulomatosis with polyangiitis (EGPA)
  • glucocorticoids
  • granulomatosis with polyangiitis (GPA)
  • immunosuppressive therapy
  • infections
  • microscopic polyangiitis (MPA)
  • plasma exchange
  • rituximab

Parmak izi

Türkiye Romatoloji Derneği ANCA ilişkili (asosiye) vaskülitler hastalık yönetimi kılavuzu' araştırma başlıklarına git. Birlikte benzersiz bir parmak izi oluştururlar.

Bundan alıntı yap